You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Concise report
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

 

Online download statistics by month:

Online download statistics by month: March 2018 to March 2024

AbstractFullPdf
Mar 201814071568380
Apr 20189621121226
May 20189231109184
Jun 2018780957107
Jul 201837948268
Aug 201826527175
Sep 201822823082
Oct 201832932979
Nov 201834235662
Dec 201823423442
Jan 201929228748
Feb 201929429155
Mar 201928828152
Apr 201923421766
May 201921020553
Jun 201918717749
Jul 201924122240
Aug 201918015662
Sep 201916014846
Oct 201913812641
Nov 201916515046
Dec 201923522745
Jan 202015013636
Feb 202015114142
Mar 202012511640
Apr 202012411142
May 202014513082
Jun 202012812164
Jul 2020918156
Aug 2020968048
Sep 202012310347
Oct 202014813669
Nov 202015011669
Dec 202012710678
Jan 20211048963
Feb 2021645454
Mar 2021968354
Apr 20211139449
May 2021958836
Jun 2021736043
Jul 202111610250
Aug 202115814364
Sep 2021917649
Oct 202112710668
Nov 202112310265
Dec 202113010459
Jan 20221049635
Feb 20221028530
Mar 20221028740
Apr 202217715160
May 202214012848
Jun 2022867844
Jul 2022827528
Aug 202214213449
Sep 202214512041
Oct 202210710352
Nov 20221199753
Dec 2022857633
Jan 202313010850
Feb 202313611836
Mar 20231108946
Apr 2023957260
May 2023655341
Jun 2023686520
Jul 2023756431
Aug 202311910969
Sep 2023777213
Oct 202318016521
Nov 202328926216
Dec 2023716329
Jan 2024666640
Feb 2024564217
Mar 20241208733
Total14369142874270